The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Overcoming Resistance to Venetoclax in AML

Sangmin Lee, MD
Published Online:4:56 PM, Mon March 4, 2019


Sangmin Lee, MD, a physician at Weill Cornell Medicine, discusses a potential way to overcome venetoclax (Venclexta) resistance in acute myeloid leukemia (AML).

Lee says that one challenge with AML is that patients still relapse and become refractory to treatments such as venetoclax. However, resistance to venetoclax has been associated with high expression of MCL-1. Compounds targeting MCL-1 seem to be promising in this treatment landscape.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.